Design of the Building Research in CRC prevention (BRIDGE-CRC) trial: a 6-month, parallel group Mediterranean diet and weight loss randomized controlled lifestyle intervention targeting the bile acid-gut microbiome axis to reduce colorectal cancer risk among African American/Black adults with obesity
This study will be the first randomized controlled trial to examine the effects of a Mediterranean diet, weight loss, or both on bile acid metabolism, the gut microbiome, and intestinal epithelial genes associated with carcinogenesis. This approach to CRC risk reduction may be especially important among African American/Blacks given their higher risk factor profile and increased CRC incidence.Trial registrationClinicalTrials.govNCT04753359. Registered on 15 February 2021. (Source: Trials)
Source: Trials - February 15, 2023 Category: Research Source Type: clinical trials
EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
Condition: Ovarian Cancer Interventions: Drug: Nivolumab; Drug: Etigilimab Sponsors: M.D. Anderson Cancer Center; Mereo BioPharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2023 Category: Research Source Type: clinical trials
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
Condition: Ovarian Cancer Intervention: Drug: Pamiparib/Tamoxifen Sponsor: Sun Yat-sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2023 Category: Research Source Type: clinical trials
